[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Subscription::
Contact us::
Site Facilities::
::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
Last site contents
:: Editorial Board
:: About Iranian Journal of Endocrinology and Metabolism
:: Volume 17, Issue 2 (8-2015) ::
2015, 17(2): 157-170 Back to browse issues page
Medullary Thyroid Cancer Screening Using the RET Proto Oncogene Genetic Marker
Mehdi Hedayati , Marjan Zarif Yeganeh , Sara Sheikholeslami , Maryam Daneshpour , Fereidoun Azizi
, hedayati@endocrine.ac.ir
Abstract:   (15988 Views)

Introduction: Thyroid carcinoma including into four types papillary, follicular, medullary, and anaplastic is the most common endocrine malignancy. Medullary thyroid carcinoma (MTC) is one of the most aggressive forms of thyroid cancer and it accounts for up to 10% of all types of this disease. The mode of inheritance of MTC is autosomal dominant and is closely related to mutations of gain of function (missense mutations) in the RET proto-oncogene, well known in MTC development. MTC occurs as hereditary (25%) and sporadic (75%) forms. Hereditary MTC also has two syndromic (multiple endocrine neoplasia type 2A, B MEN2A, MEN2B) and non-syndromic (Familial MTC, FMTC) types. Increasing advances in molecular biology, genomics, and proteomics have led to personalized therapeutic interventions. Over the last two decades, the genetic basis of tumorgenesis has provided useful screening tools for affected families. Advances in genetic screening of the RET have enabled early detection of hereditary MTCs and prophylactic thyroidectomy for relatives who may not show any symptom of the disease. In this review we emphasize the main RET mutations in the syndromic and non syndromic forms of MTC, and have tried focus on the importance of RET genetic screening for early diagnosis and management of MTC patients.

Keywords: Genetic screening, Medullary Thyroid Cancer, FMTC, MEN2A, MEN2B, RET proto-oncogene
Full-Text [PDF 2262 kb]   (3078 Downloads)    
Type of Study: Review | Subject: Genetic
Received: 2015/01/20 | Accepted: 2015/04/21 | Published: 2015/07/27
Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Hedayati M, Zarif Yeganeh M, Sheikholeslami S, Daneshpour M, Azizi F. Medullary Thyroid Cancer Screening Using the RET Proto Oncogene Genetic Marker. Iranian Journal of Endocrinology and Metabolism 2015; 17 (2) :157-170
URL: http://ijem.sbmu.ac.ir/article-1-1882-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 17, Issue 2 (8-2015) Back to browse issues page
مجله ی غدد درون‌ریز و متابولیسم ایران، دو ماهنامه  پژوهشی مرکز تحقیقات غدد درون‌ریز و متابولیسم، Iranian Journal of Endocrinology and Metabolism
Persian site map - English site map - Created in 0.06 seconds with 36 queries by YEKTAWEB 4691